Healthy, Male Clinical Trial
Official title:
An Open-label, Randomized, Single Dose, Crossover Bioequivalent Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap, 25mg in Healthy Male Volunteers
The purpose of this study is to evaluate the pharmacokinetics equivalence and safety by comparing pharmacokinetics characteristics between the SYP-1512 Tab and Revlimid cap (25mg) when administered a single-dose to healthy male volunteers.
Healthy volunteers are administrated single-dose over the period I and II (crossover) of
SYP-1512 Tab and Revlimid cap (25mg) as of lenalidomide 25mg.
Every time before and after each medication, pharmacokinetic (PK) parameters and safety of
SYP-1512 Tab and Revlimid cap (25mg) is performed using a blood sample and conducting some
tests (vital signs, physical exam, ECG, laboratory test, etc.) respectively
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03674060 -
Study to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers
|
Phase 1 |